MRK - Evolus & Urovant: Similar Strategies Opposite Reactions To Positive Catalysts
By Bill Langbein, Founder SanaCurrents
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then its shares have held stable, even touching $30 per share.
SanaCurrents, which tracks market-moving catalysts of biopharmaceutical and medical technology stocks, began following Evolus last year, and eventually released its sentiment report in January 2019 when the company was trading at around $15.50, prior to the anticipated FDA Approval